Technology Assisted Collaborative Care for Dialysis Patients
This study is testing a program called TĀCcare 2.0 to see if it can improve common symptoms like pain, tiredness (fatigue), and feeling down (depression) in people with chronic kidney disease who are on hemodialysis. TĀCcare 2.0 involves recommendations for medications and/or a type of talk therapy called Cognitive Behavioral Therapy (CBT). You would either receive this TĀCcare 2.0 program or continue with your usual medical care. The study aims to see if TĀCcare 2.0 helps reduce these symptoms over 6 months. To join, you must be at least 18 years old, have been on hemodialysis three times a week for over 3 months, and speak English or Spanish. The study is currently unclear on its recruitment status and plans to enroll 424 participants.
- Study design
- This is a multi-center study involving 424 patients from 36 dialysis clinics. Your dialysis clinic would be randomly assigned to either the TĀCcare 2.0 intervention group or the usual care group.
- What's involved
- If in the TĀCcare 2.0 group, you would receive CBT through 12 weekly telehealth sessions, either during dialysis or from home. The intervention lasts for a total of 12 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main outcomes for this study are measured at 6 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Technology Assisted Collaborative Care Intervention to Improve Patient-centered Outcomes in Dialysis Patients
At a glance
Conditions
NCT06978127
Where you'd take part
This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of Pittsburgh
Pittsburgh, Pennsylvaniastudy coordinator listed
Recruiting
UNM
Albuquerque, New Mexicostudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Manisha Jhamb, MD, MPH · PRINCIPAL_INVESTIGATOR · University of Pittsburgh
- Mark L Unruh, MS, MS · PRINCIPAL_INVESTIGATOR · University of New Mexico
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- TĀCcare 2.0 Effectiveness evaluation/Change in fatigue (co-primary outcome)6 months
Change in fatigue is a primary outcome. The Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) will be used to measure fatigue. Scores range from 0-52 with lower scores indicating greater fatigue.
- TĀCcare 2.0 Effectiveness evaluation/Change in Pain Intensity (co-primary outcome)6 months
Change in pain intensity score is also a primary outcome measure. The Brief Pain Inventory (BPI) will be used to measure pain intensity. The BPI uses a scale of 0 to 10. Higher scores on the pain intensity scale indicate greater pain severity.
- TĀCcare 2.0 Effectiveness evaluation/Change in Depression (co-primary outcome)6 months
Change in depression severity score is also a primary outcome measure. The Beck Depression Inventory-II will be used to measure the depression severity score. Each item is scored on a 4 point scale ranging from 0 to 3, allowing for a total score ranging from 0 to 63. Higher scores indicate more severe symptoms.